Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study

Lung Cancer

Volumn 80, Issue 2, 2013, Pages 197-202

  Habib, Stéfanie ^a   Delourme, Julie ^a,b   Dhalluin, Xavier ^a   Petyt, Gregory ^a,b   Tacelli, Nunzia ^a,b   Scherpereel, Arnaud ^a,b,c   Lafitte, Jean Jacques ^a,b   Cortot, Alexis B ^a,b,d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c INSERM U1019   (France)

^d INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

Bevacizumab; Fourth line; NSCLC; Paclitaxel

Indexed keywords

BEVACIZUMAB; CRIZOTINIB; DOCETAXEL; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; REFERENCE DATABASE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 84875908462     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.01.015     Document Type: Article

References (29)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
2. Johnson D.H. Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst Monogr 1995, 61-63.
3. Pasquier E., Carré M., Pourroy B., Camoin L., Rebaï O., Briand C., et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004, 3:1301-1310.
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Sweeney C.J., Miller K.D., Sissons S.E., Nozaki S., Heilman D.K., Shen J., et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61:3369-3372.
6. Shaked Y., Henke E., Roodhart J.M.L., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
7. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
8. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
9. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
10. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
11. Asahina H., Sekine I., Horinouchi H., Nokihara H., Yamamoto N., Kubota K., et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012, 13:39-43.
12. Massarelli E., Andre F., Liu D.D., Lee J.J., Wolf M., Fandi A. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39:55-61.
13. Chen Y.-M., Shih J.-F., Fan W.-C., Wu C.H., Chou K.T., Tsai C.M., et al. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. J Chin Med Assoc 2011, 74:209-214.
14. Chang M.H., Ahn J.S., Lee J., Kim K.H., Park Y.H., Han J., et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.
15. Reck M., Von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
16. Burns T.F., Juergens R.A. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology (Williston Park, NY) 2010, 24:1226. 1223-4.
17. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2 - negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
18. Miles D.W., Chan A., Dirix L.Y., Cortés J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 - negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
19. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010, 28:614-619.
20. Herbst R.S., Ansari R., Bustin F., Flynn P., Hart L., Otterson G.A., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
21. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
22. Gridelli C., Bennouna J., De Castro J., Dingemans A.M., Griesinger F., Grossi F., et al. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer 2011, 12:407-411.
23. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
24. Lee J.-O., Kim T.M., Lee S.-H., Kim D.W., Kim S., Jeon Y.K., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.
25. Dejean E., Renalier M.H., Foisseau M., Agirre X., Joseph N., de Paiva G.R., et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 2011, 25:1882-1890.
26. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
27. Saito K., Kikuchi Y., Fujii K., Kita T., Furuya K. Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs. triweekly regimens. Targeted Oncol 2006, 1:86-89.
28. Jalal S., Bedano P., Einhorn L., Bhatia S., Ansari R., Bechar N., et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 2010, 5:2008-2011.
29. Mountzios G., Emmanouilidis C., Vardakis N., Kontopodis E., Hatzidaki D., Popis E., et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer 2012, 77:146-150.